10/505239

Rec'd PCT/PTO   19 AUG 2004

SEQUENCE LISTING

<110> GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

<120> CONJUGATES OF LIGAND, LINKER AND CYTOTOXIC AGENT AND RELATED COMPOSITIONS AND METHODS OF USE

<130> 220721

<150> 60/360,543
<151> 2002-02-27

<150> 60/370,189
<151> 2002-04-05

<160> 24

<170> PatentIn version 3.1

<210> 1
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic
<400> 1
Phe Ala Leu Ala
1

<210> 2
<211> 5
<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 2

Val Leu Ala Leu Ala
1   5

<210> 3

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 3

Ala Leu Ala Leu
1

<210> 4

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 4

Ala Leu Ala Leu Ala
1   5

<210> 5

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 5

Leu Gly Pro Gln Gly Pro Pro His Leu Val Ala Asp Pro Ser Lys Lys
1   5   10   15

Gln Gly Pro Trp Leu Glu Glu Glu Glu Ala Tyr Gly Trp Met Asp
            20   25   30

Phe

<210> 6

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<220>

<221> misc_feature

<222> (2)..(2)

<223> Xaa = at position 2 is norleucine

<400> 6

Trp Xaa Asp Phe
1

<210> 7

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<220>

<221> misc_feature

<222> (2)..(2)

<223> Xaa = at position 2 is sulfotyrosine

<400> 7

Asp Xaa Met Gly Trp Met Asp Phe
1   5

<210> 8

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<220>

<221> misc_feature

<222> (2)..(2)

<223> Xaa = at position 2 is sulfotyrosine

<220>

<221> misc_feature

<222> (3)..(3)

<223> Xaa = at position 3 is norleucine

<220>

<221> misc_feature

<222> (6)..(6)

<223> Xaa = at position 6 is norleucine

<400> 8

Asp Xaa Xaa Gly Trp Xaa Asp Phe
1   5

<210> 9

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 9

Val Pro Leu Pro Ala Gly Gly Gly Thr Val Leu Thr Lys Met Tyr Pro
1   5   10   15

Arg Gly Asn His Trp Ala Val Gly His Leu Met
            20   25

<210> 10

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 10

Trp Ala Val Gly His Leu Met
1   5

<210> 11

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 11

Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
1   5   10

<210>   12

<211>   8

<212>   PRT

<213>   Artificial Sequence

<220>

<223>   Synthetic

<220>

<221>   misc_feature

<222>   (1)..(8)

<223>   wherein the peptide is carboxylated at either the N-or C- terminu
        s

<400>   12

Phe Cys Phe Trp Lys Thr Cys Thr
1   5

<210>   13

<211>   11

<212>   PRT

<213>   Artificial Sequence

<220>

<223>   Synthetic

<400>   13

Arg Pro Leu Pro Gln Gln Phe Phe Gly Leu Met
1   5   10

<210>   14

<211>   15

<212>   PRT

<213>   Artificial Sequence

                                Page 6

<220>

<223> Synthetic

<400> 14

Pro Gly Thr Cys Glu Ile Cys Ala Tyr Ala Ala Cys Thr Gly Cys
1   5   10   15

<210> 15

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 15

Asn Asp Asp Cys Glu Leu Cys Val Ala Cys Thr Gly Cys Leu
1   5   10

<210> 16

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 16

Asn Tyr Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Phe
1   5   10   15

<210> 17

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<223>   Synthetic

<400>   17

His Ser Asp Ala Leu Phe Thr Asp Asn Tyr Thr Arg Leu Arg Leu Gln
1   5   10   15

Met Ala Val Lys Lys Tyr Leu Asn Ser Ile Leu Asn Gly
            20   25

<210>   18

<211>   29

<212>   PRT

<213>   Artificial Sequence

<220>

<223>   Synthetic

<220>

<221>   misc_feature

<222>   (17)..(17)

<223>   Xaa = at position 17 is norleucine

<400>   18

His Ser Asp Ala Leu Phe Thr Asp Asn Tyr Thr Arg Leu Arg Leu Gln
1   5   10   15

Xaa Ala Val Lys Lys Tyr Leu Asn Ser Ile Leu Asn Gly
            20   25

<210>   19

<211>   7

<212>   PRT

<213>   Artificial Sequence

<220>

<223>   Synthetic

<220>

<221> misc_feature

<222> (5)..(5)

<223> Xaa = at position 5 is norleucine

<400> 19

Ala Tyr Gly Trp Xaa Asp Phe
1   5

<210> 20

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<220>

<221> misc_feature

<222> (8)..(8)

<223> Xaa = at position 8 is norleucine

<400> 20

Glu Glu Glu Ala Tyr Gly Trp Xaa Asp Phe
1   5   10

<210> 21

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<220>

<221> misc_feature

<222> (1)..(1)

<223> Xaa = at position 1 is 2-cyclohexyl-L-alanine

<400> 21

Xaa Leu Ala Leu Ala
1   5

<210> 22

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic

<220>

<221> misc_feature

<222> (1)..(1)

<223> Xaa = at position 1 is 2-cyclohexyl-L-alanine

<220>

<221> misc_feature

<222> (2)..(2)

<223> Xaa = at position 2 is 2-cyclohexyl-L-alanine

<400> 22

Xaa Xaa Leu Ala Leu
1   5

<210> 23

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223>   Synthetic

<220>

<221>   misc_feature

<222>   (1)..(1)

<223>   Xaa = at position 1 is 1-naphtyl-alanine

<220>

<221>   misc_feature

<222>   (2)..(2)

<223>   Xaa = at position 2 is 2-cyclohexyl-L-alanine

<400>   23

Xaa Xaa Leu Ala Leu
1   5

<210>   24

<211>   5

<212>   PRT

<213>   Artificial Sequence

<220>

<223>   Synthetic

<220>

<221>   misc_feature

<222>   (1)..(1)

<223>   Xaa = at position 1 is 1-naphtyl-alanine

<400>   24

Xaa Leu Ala Leu Ala
1   5